ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

9:00AM-11:00AM: Abstract Number: 1645

Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1792

Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

9:00AM-11:00AM: Abstract Number: 1625

Pneumocystis Jiroveci Pneumonia in Immunocompromised Patients with Rheumatologic Disease in a Single, Tertiary Medical Center

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1698

Polyarthritis Workup in Primary Care Setting : How Are We Doing?

Professional Education Poster

9:00AM-11:00AM: Abstract Number: 1692

Poor Physical Activity Levels and Cardiorespiratory Fitness Among Patients with Childhood-Onset Takayasu Arteritis in Remission

Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

9:00AM-11:00AM: Abstract Number: 1722

Predicting Rheumatoid Arthritis Using the Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Abstract Number: 1752

Prediction of Responder and Non-responder to JAK Inhibitors in Patients with Rheumatoid Arthritis: A Pilot Study with Integrative Cluster Analysis

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Abstract Number: 1935

Predictors of Early Mortality for Giant Cell Arteritis at the Time of Diagnosis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1893

Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

9:00AM-11:00AM: Abstract Number: 1716

Predictors of Unacceptable Pain and Unacceptable Pain with Low Inflammation in Early Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Abstract Number: 1944

Predictors of Visual Loss and Cerebrovascular Accidents in Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1781

Pregnancy After Bariatric Surgery in Women with Rheumatic Diseases and Association with Adverse Birth Outcomes

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1639

Preliminary Baseline Subject Demographics and Disease Characteristics in a Phase 3 Clinical Trial of the Safety and Efficacy of Lenabasum in Dermatomyositis (DETERMINE)

Miscellaneous Rheumatic & Inflammatory Diseases Poster III: Therapies

9:00AM-11:00AM: Abstract Number: 1758

Prevalence and Incidence of Infection and Venous Thromboembolism in Rheumatoid Arthritis Patients Newly Initiating Various DMARD Classes: Real-World Analysis of 2012–2016 US Medicare Data

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Abstract Number: 1719

Prevalence and Trajectory of Erosions, Synovitis, and Bone Marrow Edema in Feet of Patients with Early Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].